Casopitant

Casopitant

220px
Systematic (IUPAC) name
(2S,4S)-4-(4-Acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide
Identifiers
CAS Number	414910-27-3
ATC code	A04AD13 (WHO)
PubChem	CID: 23725089
ChemSpider	25069049
UNII	3B03KPM27L Y
ChEMBL	CHEMBL2107320
Chemical data
Formula	C30H35F7N4O2
Molecular mass	616.26 g/mol
SMILES CC1=C(C=CC(=C1)F)[C@@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C
InChI InChI=1S/C30H35F7N4O2/c1-18-13-24(31)5-6-26(18)27-17-25(40-11-9-39(10-12-40)20(3)42)7-8-41(27)28(43)38(4)19(2)21-14-22(29(32,33)34)16-23(15-21)30(35,36)37/h5-6,13-16,19,25,27H,7-12,17H2,1-4H3/t19-,25-,27+/m1/s1 Key:XGGTZCKQRWXCHW-JRLVAEJTSA-N
(verify)

Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK₁) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV). It is currently under development by GlaxoSmithKline (GSK).

In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.

See also

• Aprepitant
• Fosaprepitant
• L-733,060
• Maropitant
• Vestipitant

References

1. REDIRECT Template:Peptide receptor modulators